v
Search
Advanced
    Review Article Open Access
    Gluten-free Diet and Metabolic Dysfunction-associated Steatotic Liver Disease: Mechanisms and Therapeutic Potential
    Di Meng, Zhenyao Jiang, Yingcheng Yao, Mingming Ye, Sitian Zhao, Mingyang Jin, Jie Li, Junping Shi
    Journal of Clinical and Translational Hepatology, Published online November 16, 2026. doi:10.14218/JCTH.2026.00242
    Abstract
    Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic liver disease associated with obesity, insulin resistance, and metabolic syndrome and has become a [...] Read more.

    Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic liver disease associated with obesity, insulin resistance, and metabolic syndrome and has become a major global health challenge. Current management relies primarily on comprehensive lifestyle interventions, including dietary modification, regular physical activity, weight loss, management of metabolic risk factors, and emerging pharmacotherapies. The gluten-free diet (GFD) was originally developed for the treatment of celiac disease and has attracted attention in recent years for its potential metabolic benefits. Existing studies suggest that gluten- or wheat-targeted dietary interventions may affect MASLD-related pathways, including the gut microbiota, inflammation, insulin sensitivity, and liver fat accumulation. In patients with concurrent celiac disease and MASLD, a GFD is indicated for celiac disease, but its hepatic and metabolic effects are variable. However, clinical and mechanistic evidence for its potential effects in patients with non-celiac MASLD is limited and heterogeneous, relying largely on indirect evidence from animal models; furthermore, long-term, unsupervised adherence to a GFD may adversely affect metabolic health. This narrative review critically evaluates the therapeutic boundaries of gluten-targeted interventions, compares the gluten-free diet with established dietary patterns, and outlines challenges related to nutritional adequacy, cost, and adherence. Future research should focus on high-quality randomized controlled trials to identify the specific benefits and risks of gluten removal in patients with non-celiac MASLD and to inform more precise dietary guidance.

    Full article
    Review Article Open Access
    Chronic Constipation: Mechanisms and Roadmap for Testing Candidate Endotypes
    Elena Bonora, Elisa Boschetti, Visha Parmar, Saranya Arumugam, Roberto De Giorgio, Shanthi Srinivasan, John W. Wiley
    Journal of Translational Gastroenterology, Published online November 16, 2026. doi:10.14218/JTG.2026.00033
    Abstract
    Chronic constipation is common, heterogeneous, and often incompletely controlled. This review evaluates cellular and molecular evidence and proposes a roadmap for testing candidate [...] Read more.

    Chronic constipation is common, heterogeneous, and often incompletely controlled. This review evaluates cellular and molecular evidence and proposes a roadmap for testing candidate endotypes. We distinguish established physiology and clinical efficacy from human associations, causal effects in experimental systems, and unvalidated hypotheses. Relevant mechanisms involve enteric neurons and glia, pacemaker and smooth muscle networks, epithelial transport, enteroendocrine signaling, microbial metabolites, and pelvic floor coordination. Five candidate endotypes address neuronal composition, pacemaker dysfunction, methanogen enrichment, neuroimmune activation, and cortical–pelvic coordination; pharmacogenomics provides a cross-cutting strategy. Each proposal links measurable features to appropriate sampling and prospective tests that can exclude clinically meaningful effects. Cellular sequencing, spatial RNA and protein profiling, and multimodal integration can identify candidate signatures. Organoid and animal perturbations test mechanisms within models; clinical usefulness additionally requires reproducible assays, independent validation, randomized treatment-interaction tests, and patient benefit. Rome V criteria provide a cohort framework, with the criteria version recorded explicitly. A staged program should begin with clinical phenotyping and biospecimen banking, add mucosal studies, and develop multicenter full-thickness tissue collections for neuromuscular questions. This approach addresses cost, selection bias, and tissue access while distinguishing mechanistic discovery from useful treatment guidance.

    Full article
    Original Article Open Access
    UGT1A1 Mutations and Clinical Features in Hereditary Unconjugated Hyperbilirubinemia: A Chinese Cohort Study
    Xuheng Teng, Xiaoxiao Mi, Chun Liu, Rongqiang Liu, Zhichao Zhou, Wenjun Yang, Gongying Chen, Junping Shi, Ling Gong
    Journal of Clinical and Translational Hepatology, Published online November 13, 2026. doi:10.14218/JCTH.2026.00479
    Abstract
    Hereditary unconjugated hyperbilirubinemia is most often caused by UGT1A1 mutations and includes Gilbert syndrome, Crigler-Najjar syndrome types I and II, and prolonged neonatal [...] Read more.

    Hereditary unconjugated hyperbilirubinemia is most often caused by UGT1A1 mutations and includes Gilbert syndrome, Crigler-Najjar syndrome types I and II, and prolonged neonatal unconjugated hyperbilirubinemia. In Chinese patients, however, the variant spectrum and its clinical relevance remain incompletely characterized. We therefore aimed to define the UGT1A1 variant profile and assess genotype-phenotype correlations in a Chinese cohort.

    We retrospectively analyzed 163 patients from the Affiliated Hospital of Hangzhou Normal University (2016–2025). Sanger sequencing of UGT1A1 was performed, covering the enhancer, promoter, and all coding regions. The association between variant types and total serum bilirubin levels was evaluated.

    UGT1A1 variants were detected in 156 patients (95.7%), covering 19 distinct variants, including two previously unreported candidate variants (c.272C>G and c.556delinsAATGG). The most common alleles were c.-3279T>G (allele frequency: 0.68), (TA)6>(TA)7 (0.49), and p.G71R (0.23). Coding-region variants were observed more frequently in the Crigler-Najjar syndrome type II group than in the Gilbert syndrome group (P < 0.05), while total bilirubin levels were higher with both coding and non-coding variants than with non-coding variants alone (adjusted P < 0.05 by Dunn’s test), although median-regression confidence intervals included zero.

    UGT1A1 genotyping yields a variant detection rate of 95.7% and identifies two previously unreported candidate variants in this Chinese cohort. Exploratory analyses suggest higher bilirubin levels in patients carrying both coding and non-coding variants than in those carrying non-coding variants alone, warranting confirmation in larger cohorts.

    Full article
All Journals
    Review Article Open Access
    Environmental Triggers’ Involvement in the Development of Type 1 Diabetes Mellitus
    Tajudeen Olanrewaju Yahaya, Umar Usman Liman, Caleb Dikko Obadiah, Zafira Illo Zakari, Daniel Anyebe, Boniface Gomo Clement, Balkisu Marafa Muhammad
    Exploratory Research and Hypothesis in Medicine, Published online July 27, 2022. doi:10.14218/ERHM.2022.00051
    Abstract
    The huge burden of type 1 diabetes mellitus (T1DM) has been a source of concern globally since the Industrial Revolution in the 18th–19th centuries. To this end, studies have shown [...] Read more.

    The huge burden of type 1 diabetes mellitus (T1DM) has been a source of concern globally since the Industrial Revolution in the 18th–19th centuries. To this end, studies have shown that certain environmental changes that accompanied the Revolution may have increased the risk and burden of the disease in genetically predisposed individuals. However, documented studies that synthesize these environmental triggers are scarce. As a result, the current study was conceived to synthesize the environmental triggers of T1DM to boost public awareness. Relevant information was retrieved from reputable academic databases; namely, Scopus, PubMed, SpringerLink, and Embase. The results showed that chemical exposure, viral infection, gut microbiome disruption, vitamin and mineral deficiencies, inadequate or exclusive breastfeeding, as well as early exposure to infant feeding formulas could increase the risk and burden of T1DM in genetically predisposed individuals. As a consequence, these triggers could compromise the expression of certain genes involved in insulin synthesis and immune function, such as the human leukocyte antigen (HLA), insulin (INS), cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), and protein tyrosine phosphatase non-receptor type 22 (PTPN22) genes. This would result in a dysfunctional immune system in which immune cells, such as T-cells and B-cells and molecules, such as cytokines would attack self-tissues, thus causing autoimmunity of the pancreatic beta cells. Environmental triggers could also induce the T1DM pathophysiology by modifying the epigenome of the mentioned genes. Furthermore, some epigenetic changes could be reversed, which would infer that treatment procedures that would include the pathophysiology of the environmental triggers could be more effective.

    Full article
    Original Article Open Access
    Overexpression of RBM34 Promotes Tumor Progression and Correlates with Poor Prognosis of Hepatocellular Carcinoma
    Wei Wang, Rui Zhang, Ning Feng, Longzhen Zhang, Nianli Liu
    Journal of Clinical and Translational Hepatology, Published online July 13, 2022. doi:10.14218/JCTH.2022.00166
    Abstract
    Emerging evidence suggests that RNA-binding motif (RBM) proteins are involved in hepatocarcinogenesis and act either as oncogenes or tumor suppressors. The objective of this study [...] Read more.

    Emerging evidence suggests that RNA-binding motif (RBM) proteins are involved in hepatocarcinogenesis and act either as oncogenes or tumor suppressors. The objective of this study was to investigate the role of RBM34, an RBM protein, in hepatocellular carcinoma (HCC).

    We first examined the expression of RBM34 across cancers. The correlation of RBM34 with clinicopathological features and the prognostic value of RBM34 for HCC was then investigated. Functional enrichment analysis of RBM34-related differentially expressed genes (DEGs) was performed to explore its biological function. RNA sequencing (RNA-seq) was applied to identify downstream genes and pathways affected upon RBM34 knockout. The correlation of RBM34 with immune characteristics was also analyzed. The oncogenic function of RBM34 was examined in in vitro and in vivo experiments.

    RBM34 was highly expressed in hepatocellular carcinoma and correlated with poor clinicopathological features and prognosis. RBM34 was positively associated with tumor immune cell infiltration, biomarkers of immune cells, and immune checkpoint expression. A positive correlation was also observed between RBM34, T cell exhaustion, and regulatory T cell marker genes. Knockout of RBM34 significantly inhibited cell proliferation, migration, and xenograft tumor growth, and sensitized HCC cells to sorafenib treatment. RBM34 inhibition reduced FGFR2 expression and affected PI3K-AKT pathway activation in HCC cells.

    Our study suggests that RBM34 may serve as a new prognostic marker and therapeutic target of HCC.

    Full article
    Original Article Open Access
    Naringenin is a Potential Immunomodulator for Inhibiting Liver Fibrosis by Inhibiting the cGAS-STING Pathway
    Li Chen, Siwei Xia, Shuqi Wang, Yuanyuan Zhou, Feixia Wang, Zhanghao Li, Yang Li, Desong Kong, Zili Zhang, Jiangjuan Shao, Xuefen Xu, Feng Zhang, Shizhong Zheng
    Journal of Clinical and Translational Hepatology, Published online April 28, 2022. doi:10.14218/JCTH.2022.00120
    Abstract
    Naringenin is an anti-inflammatory flavonoid that has been studied in chronic liver disease. The mechanism specific to its antifibrosis activity needs further investigation This [...] Read more.

    Naringenin is an anti-inflammatory flavonoid that has been studied in chronic liver disease. The mechanism specific to its antifibrosis activity needs further investigation This study was to focused on the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) pathway in hepatic stellate cells and clarified the antifibrosis mechanism of naringenin.

    The relationship between the cGAS-stimulator of interferon genes (STING) pathway and liver fibrosis was analyzed using the Gene Expression Omnibus database. Histopathology, immunohistochemistry, fluorescence staining, Western blotting and polymerase chain reaction were performed to assess gene and protein expression levels associated with the cGAS pathway in clinical liver tissue samples and mouse livers. Molecular docking was performed to evaluate the relationship between naringenin and cGAS, and western blotting was performed to study the expression of inflammatory factors downstream of cGAS in vitro.

    Clinical database analyses showed that the cGAS-STING pathway is involved in the occurrence of chronic liver disease. Naringenin ameliorated liver injury and liver fibrosis, decreased collagen deposition and cGAS expression, and inhibited inflammation in carbon tetrachloride (CCl4)-treated mice. Molecular docking found that cGAS may be a direct target of naringenin. Consistent with the in vivo results, we verified the inhibitory effect of naringenin on activated hepatic stellate cells (HSCs). By using the cGAS-specific agonist double-stranded (ds)DNA, we showed that naringenin attenuated the activation of cGAS and its inflammatory factors affected by dsDNA. We verified that naringenin inhibited the cGAS-STING pathway, thereby reducing the secretion of inflammatory factors by HSCs to ameliorate liver fibrosis.

    Interrupting the cGAS-STING pathway helped reverse the fibrosis process. Naringenin has potential as an antihepatic fibrosis drug.

    Full article
Special Features

Call for Papers for Special Issue 'Practical Updates in Breast Pathology: Common and Rare Diseases'

Journal: Journal of Clinical and Translational Pathology
Special Issue: Practical Updates in Breast Pathology: Common and Rare Diseases
Submission deadline: Auguest 31, 2026
Publication date: An article will be published online as soon as it is accepted

Call for Papers for Special Issue 'Advances in Digital Pathology and AI in Pathology'

Journal: Journal of Clinical and Translational Pathology
Special Issue: Advances in Digital Pathology and AI in Pathology
Submission deadline: December 31, 2025
Publication date: An article will be published online as soon as it is accepted

Call for Papers for Special Issue 'Contributions to the GYN Pathology'

Journal: Journal of Clinical and Translational Pathology
Special Issue: Contributions to the GYN Pathology
Submission deadline: March 31, 2025
Publication date: An article will be published online as soon as it is accepted

Call for Papers for Special Issue ‘New Translational Challenges in Primary Biliary Cholangitis’

Journal: Journal Clinical and Translational Hepatology
Special Issue: New Translational Challenges in Primary Biliary Cholangitis
Submission deadline: June 30, 2023
Publication date: An article will be published online as soon as it is accepted

Call for Papers for Special Issue ‘A Spotlight on Progress and Pitfalls in NAFLD/MAFLD Studies, 2022’

Journal: Journal of Clinical and Translational Hepatology
Special Issue: A Spotlight on Progress and Pitfalls in NAFLD/MAFLD Studies, 2022
Submission deadline: March 30, 2023
Publication date: An article will be published online as soon as it is accepted

Call for Papers for Special Issue 'Comparative study of traditional medicine in the world'

Journal: Future Integrative Medicine
Special Issue: Comparative study of traditional medicine in the world
Submission deadline: June 30, 2023
Publication date: An article will be published online as soon as it is accepted

Call for Papers for Special Issue 'Therapeutic effects of herbal medicines on neurological impairment and related mental disorders based on the evidence of clinical and basic studies'

Journal: Future Integrative Medicine
Special Issue: Therapeutic effects of herbal medicines on neurological impairment and related mental disorders based on the evidence of clinical and basic studies
Submission deadline: June 30, 2023
Publication date: An article will be published online as soon as it is accepted

Call for Papers for Special Issue ‘Immunoregulatory Mechanisms of Herbal Medicines in Cancer and Infectious Diseases’

Journal: Future Integrative Medicine
Special Issue: Immunoregulatory Mechanisms of Herbal Medicines in Cancer and Infectious Diseases
Submission deadline: June 30, 2023
Publication date: An article will be published online as soon as it is accepted
Back to Top